蒲地蓝消炎口服液联合α-干扰素对小儿急性上呼吸道感染的临床疗效及作用机制研究

Clinical efficacy and mechanism of Pudilan antiinflammatory oral liquid combined withα-interferon on acute upper respiratory tract infection in children

目的探讨蒲地蓝消炎口服液联合α-干扰素治疗小儿急性上呼吸道感染的临床疗效及作用机制。方法选取2020年6月至2021年6月本院收治的86例急性上呼吸道感染患儿作为研究对象,随机分为观察组和对照组,每组43例。对照组给予α-干扰素治疗,观察组在对照组基础上给予蒲地蓝消炎口服液液治疗,比较两组临床疗效、治疗前后相应症状及体征出现情况、症状恢复时间及炎症因子水平。结果观察组治疗总有效率为90.70%,高于对照组的76.64%,差异有统计学意义(P<0.05)。治疗后,两组发热、咽喉肿痛、流涕、咽部充血、扁桃体肿大发生率均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组发热、咽喉肿痛、流涕症状恢复时间均短于对照组,差异有统计学意义(P<0.05)。治疗1周后,两组白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。结论采取α-干扰素联合蒲地蓝消炎口服液治疗上呼吸道感染患儿效果显著,可缩短恢复时间,改善炎症因子水平,值得临床推广应用。

Objective To investigate the clinical efficacy and mechanism of Pudilan anti-inflammatory oral liquid combined withα-interferon in the treatment of acute upper respiratory tract infection in children.Methods 86 cases of children with acute upper respiratory tract infection in our hospital June 2020 to June 2021 were selected as the research subjects,and they were randomly divided into observation group and control group,with 43 cases in each group.The control group was treated withα-interferon,and the observation group was treated with Pudilan anti-inflammatory oral liquid on the basis of the control group,the clinical efficacy,the corresponding symptoms and signs before and after treatment,recovery time of symptoms and the levels of inflammatory factors were compared between the two groups.Results The total effective rate of treatment in the observation group was 90.70%,which was higher than 76.64%in the control group,and the difference was statistically significant(P<0.05).After treatment,the incidences of fever,sore throat,runny nose,pharyngeal congestion,and enlarged tonsils in the two groups were lower than those before treatment,and the observation group was lower than the control group,and the difference was statistically significant(P<0.05).The recovery time of symptoms of fever,sore throat and runny nose in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After 1 week of treatment,the levels of interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)in the two groups were lower than those before treatment,and the observation group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion Takingα-interferon combined with Pudilan anti-inflammatory oral liquid in the treatment of children with upper respiratory tract infection has significant effect,can shorten the recovery time and improve the level of inflammatory factors,which is worthy of clinical application.